Compare Multiple Daily Injections With Carbohydrate Counting or With Simplified Qualitative Meal-Size Estimation in Type 1 Diabetes
Launched by DASMAN DIABETES INSTITUTE · Jun 17, 2025
Trial Information
Current as of July 09, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Males and females ≥ 21 years of age.
- • 2. Clinical diagnosis of T1D for at least 12 months. The diagnosis of T1D is based on the investigator's judgment; C-peptide level and antibody determinations are not needed.
- • 3. On MDI therapy.
- • 4. Previously trained to count carbohydrates through a structured education program or known to perform carbohydrate counting by their educator/ dietitian.
- • 5. Baseline HbA1c value ≥ 7.5% and \< 11% (up to 7 days before or after screening)
- Exclusion Criteria:
- • 1. Serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator.
- • 2. Failure to comply with the study protocol or with team's recommendations.
- • 3. Injection of isophane insulin (NPH) or any intermediate-acting insulin.
- • 4. More than 1 slow-acting injection and unwilling to switch to once a day for the study
- • 5. Current or ≤ 1 month use of other antihyperglycemic agents (SGLT2, GLP-1, Metformin, Acarbose, etc.).
- • 6. Pregnancy.
- • 7. Severe hypoglycemic episode within one month of admission.
- • 8. Severe diabetic ketoacidosis episode within one month of admission.
- • 9. Clinically significant nephropathy, neuropathy, or retinopathy as judged by the investigator.
- • 10. Conditions that may interfere with accurate HbA1c levels: clinically significant anemia, hemoglobinopathy, or a recent blood transfusion as judged by the investigator.
About Dasman Diabetes Institute
Dasman Diabetes Institute (DDI) is a leading research and clinical organization dedicated to advancing diabetes care and management through innovative research, education, and community outreach. Established to address the growing prevalence of diabetes, DDI focuses on conducting high-quality clinical trials aimed at developing effective prevention and treatment strategies. The institute collaborates with local and international partners to enhance understanding of diabetes and its complications, fostering a multidisciplinary approach that integrates clinical practice with cutting-edge research. With a commitment to improving patient outcomes, DDI serves as a vital resource for healthcare professionals, researchers, and individuals affected by diabetes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kuwait City, , Kuwait
Patients applied
Trial Officials
Ebaa Al Ozairi, MD
Principal Investigator
Dasman Diabetes Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported